Altogether, our clinical data not only qualify plasma Hsp90α as a novel diagnostic biomarker for breast cancer, but also indicate the involvement of eHsp90α in the lymphatic metastasis process of breast cancer. Here, HSP90AA1 is linked to breast carcinoma.